8-K: Barinthus Bio Merges with Clywedog Therapeutics

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, with key clinical milestones expected within 18 months.

Summary

• Barinthus Biotherapeutics plc (BRNS) and Clywedog Therapeutics, Inc. are combining in an all-stock merger.
• The combined company will be renamed Clywedog Therapeutics, Inc. and is expected to trade on the NASDAQ under the new ticker symbol CLYD.
• Clywedog stockholders are expected to own approximately 66% and Barinthus Bio shareholders approximately 34% of the combined company on a fully diluted basis.
• The combined pipeline will comprise three clinical-stage product candidates: CLY-101 (Type 1 and Type 2 Diabetes), CLY-201 (Type 1 Diabetes), and VTP-1000 (Celiac Disease).
• Four key value-driving clinical milestones are expected within 18 months of the closing, including clinical proof of concept in multiple indications.
• The estimated cash runway for the combined company extends through 2027.
• A partial tender offer to acquire shares of the combined company, up to $27 million, may be commenced for Barinthus Bio shareholders prior to closing.

Sentiment

Score: 7

Explanation: The filing announces a strategic merger with a diversified pipeline and clear milestones, backed by significant investors, suggesting a positive outlook despite inherent risks and the future nature of the transaction.

Positives

• The merger creates a diversified pipeline with three differentiated, clinical-stage product candidates targeting metabolic and autoimmune diseases.
• Four key value-driving clinical milestones are expected within 18 months, including clinical proof of concept in multiple indications.
• The estimated cash runway for the combined company extends through 2027, providing financial stability.
• The combined company will be backed by existing investors OrbiMed and Torrey Pines Investment LLC, and new investors.
• CLY-101 has the potential to work synergistically with blockbuster GLP-1 agonists, offering a comprehensive approach to diabetes management.
• Clywedog's approach for Type 1 diabetes provides the potential for a multi-component regimen, combining assets to prevent inflammation and stimulate beta islet production.
• The transaction was unanimously approved by the Boards of Directors of both companies.

Negatives

• Barinthus Bio American Depositary Shares (ADSs) will no longer trade on NASDAQ after the transaction closes.
• The transaction is subject to various approvals, including stockholder and regulatory approvals, which could introduce delays or complications.
• There is a risk that the anticipated benefits of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Integration of the two companies post-closing may not occur as anticipated, potentially affecting growth prospects.
• The proposed transaction may involve unexpected costs, liabilities, or delays.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which could adversely affect the businesses of both companies and the price of their respective securities.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction.
• There is a potential failure to receive required approvals, including stockholder approvals from both companies and the sanction of the High Court of Justice of England and Wales for the Scheme of Arrangement, and failure to satisfy other closing conditions, including the Self-Tender Offer.
• The transaction may involve unexpected costs, liabilities, or delays.
• The announcement, pendency, or completion of the proposed transaction could affect the ability of either company to attract, motivate, retain, and hire key personnel and maintain relationships with customers, distributors, and suppliers.
• The proposed transaction may divert management's attention from ongoing business operations.
• There is a risk of legal proceedings related to the proposed transaction, which could result in expense or delay.
• Either company may be adversely affected by other economic, business, and/or competitive factors.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Merger Agreement.
• Restrictions during the pendency of the proposed transaction may impact the ability of either company to pursue certain business opportunities or strategic transactions.
• There is a risk that governmental and regulatory approvals required for the proposed transaction may not be obtained, or that such approvals may delay consummation or result in conditions that reduce anticipated benefits or cause abandonment.
• The anticipated benefits of the proposed transaction may not be fully realized or may take longer to realize than expected.
• The combined company may not be able to achieve the growth prospects expected from the transaction.
• The implementation of business models and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products, pose risks.
• The scope, progress, results, and costs of developing product candidates, including preclinical studies and clinical trials, are uncertain.
• The timing and costs involved in obtaining and maintaining regulatory approval for current or future product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product, are risks.
• The market for, adoption, pricing, and reimbursement of product candidates, and the ability to compete with rapidly growing and evolving therapies and procedures, are uncertain.
• Uncertainties in contractual relationships, including collaborations, partnerships, licensing, or other arrangements, and the performance of third-party suppliers and manufacturers, exist.
• The ability to establish and maintain intellectual property protection for product candidates and products or avoid or defend claims of infringement is a risk.
• Exposure to inflation, currency rate, and interest rate fluctuations, and risks associated with doing business locally and internationally, as well as fluctuations in the market price of Barinthus Bio ADSs, are factors.
• Risks relating to competition within the industry in which each company operates are present.
• The unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities, could have an impact.
• The termination of any license agreements and/or collaboration agreements may impact the combined company's ability to license in additional programs in the future and could result in delays or unforeseen costs.

Future Outlook

The combined company, Clywedog Therapeutics, aims to advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. The estimated cash runway for the combined company extends through 2027, providing a stable financial outlook for continued development.

Management Comments

• "We believe that the combination of Barinthus Bio and Clywedog will create immediate value and long-term upside for all stakeholders by diversifying our pipeline and increasing the number of meaningful clinical milestones. The combined team will bring a deep scientific understanding of metabolic and autoimmune spaces together with strong clinical development experience, positioning us well to execute for patients and shareholders." Bill Enright, Chief Executive Officer of Barinthus Bio (who will serve as Chief Executive Officer of the combined company).
• "I am honored to have the opportunity to lead an exceptional team and am truly excited to advance our highly differentiated pipeline of disease modifying therapies for Type 1 and Type 2 diabetes, and celiac disease." Bill Enright.
• "I am excited to be part of the combined company as we strive to develop potentially disease-modifying therapies for diabetes and autoimmune disorders." Dr. Iain Dukes, a venture partner at OrbiMed (who will serve as Executive Chairman of Clywedog Therapeutics after the transaction closes).

Industry Context

This merger creates a new entity with a diversified pipeline in the high-growth metabolic and autoimmune disease sectors. The strategic combination of assets, particularly CLY-101's potential synergy with GLP-1 agonists, positions the combined company to address significant unmet medical needs and compete in a rapidly evolving therapeutic landscape. The backing by existing and new investors, including OrbiMed and Torrey Pines, signals confidence in the combined entity's strategic direction and market potential.

Comparison to Industry Standards

• The combined company's pipeline of three clinical-stage product candidates (CLY-101, CLY-201, VTP-1000) represents a robust portfolio for a biopharmaceutical company, comparable to well-capitalized peers in the clinical development stage.
• The focus on Type 1 and Type 2 Diabetes and Celiac Disease targets large global patient populations with significant unmet medical needs, aligning with high-value indications pursued by leading biopharma companies.
• The estimated cash runway through 2027 provides a solid financial foundation, which is a competitive advantage for clinical-stage biotechs, often facing capital constraints.
• The strategic approach of CLY-101, which stimulates pancreatic islet regeneration and has potential synergy with GLP-1 agonists, offers a differentiated mechanism compared to many existing or developing diabetes therapies that primarily focus on insulin sensitivity or secretion without regeneration.
• The multi-component regimen strategy for Type 1 diabetes, combining inflammation halting (CLY-201) with beta islet stimulation (CLY-101), is an innovative and potentially more comprehensive approach than single-target therapies in the T1D space.

Management Changes

Corporate Governance

Legal Proceedings

• No pending or threatened legal proceedings against Clywedog or its subsidiaries, or any Clywedog Associate (in their capacity as such) that challenges or interferes with the Contemplated Transactions.
• No outstanding orders to which Clywedog or any of its subsidiaries, or any of their material assets, are subject that would prevent or materially delay the Contemplated Transactions.
• No pending or threatened legal proceedings against Beacon or any of its subsidiaries that would have a Beacon Material Adverse Effect or prevent or materially delay the merger.
• No outstanding judgment, injunction, rule, order, or decree of any court or Governmental Authority to which Beacon or its subsidiaries are subject or in violation of, that would have a Beacon Material Adverse Effect or prevent or materially delay the merger.

Related Party Transactions

• Certain shareholders of Beacon, holding approximately 25% of its outstanding share capital, have entered into voting and support deeds with Clywedog.
• Certain stockholders of Clywedog, holding 100% of its voting power, have entered into voting and support agreements with Beacon.
• Certain officers, directors, and shareholders of Clywedog (who will become Topco shareholders) and certain officers and directors of Beacon (who will continue as officers or directors of Topco) have entered into lock-up agreements for a period of six months following the closing date.
• The combined company will receive additional investments from OrbiMed and Torrey Pines Investment LLC, both existing shareholders in Clywedog, and new investors.

Stakeholder Impact

• **Shareholders (Barinthus Bio)**: Will receive one share of common stock in the new combined company for each ADS or ordinary share owned. They may also participate in a partial tender offer of up to $27 million. Their ownership will be approximately 34% of the combined company, and Barinthus Bio ADSs will cease trading on NASDAQ.
• **Stockholders (Clywedog)**: Will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned. Their ownership will be approximately 66% of the combined company.
• **Employees**: Equity awards (options, restricted share units) will be converted into Topco equity awards with substantially similar terms. The management team of the combined company will include key personnel from both entities.
• **Customers/Suppliers**: The announcement acknowledges the potential effect on relationships with customers, distributors, and suppliers, with management aiming to maintain these relationships.
• **Regulatory Bodies**: The transaction requires approvals from various regulatory authorities, including the SEC, Nasdaq, antitrust authorities, and the High Court of Justice of England and Wales, indicating significant regulatory oversight.

Next Steps

• The combined company will be renamed Clywedog Therapeutics, Inc. and is expected to trade on NASDAQ under the new ticker symbol CLYD.
• Barinthus Bio ADSs will no longer trade on NASDAQ upon closing.
• Topco, in cooperation with Beacon and Clywedog, will prepare and file a registration statement on Form S-4 with the SEC.
• Beacon will mail a proxy statement to its shareholders.
• Stockholder approvals from both Barinthus Bio and Clywedog are required.
• Regulatory approvals, including antitrust and the sanction of the Scheme of Arrangement by the High Court of Justice of England and Wales, must be obtained.
• Topco may commence a partial tender offer to acquire up to $27 million in shares from Barinthus Bio shareholders.
• The Topco Board of Directors will be increased, with Beacon designees representing at least 1/3 and Clywedog designees at least 2/3.
• The Topco Board will adopt an Equity Incentive Plan and an Employee Stock Purchase Plan (ESPP), subject to shareholder approval.
• Clywedog will furnish audited financial statements and unaudited interim financial statements by October 27, 2025.
• Beacon will furnish unaudited interim financial statements for the quarter ended September 30, 2025, by October 27, 2025.
• Top-line data from the SAD portion of the Phase 1 AVALON study (VTP-1000) is expected in Q4 2025.
• Top-line data from the MAD portion of the Phase 1 AVALON study (VTP-1000) is expected in mid-2026.
• First top-line data readout for the Phase 2A proof of principle study in Type 2 diabetes patients (CLY-101) is expected in the second half of 2026.
• First top-line data readout for the Phase 2A proof of principle study in Type 1 diabetes (Stage 3) patients (CLY-101) is expected in the second half of 2026.

Key Dates

Recommendation

The merger of Barinthus Bio and Clywedog Therapeutics represents a significant strategic shift, creating a new entity with a diversified clinical-stage pipeline in metabolic and autoimmune diseases and an extended cash runway through 2027. While the potential for value creation is substantial, the transaction is subject to numerous closing conditions, regulatory approvals, and inherent integration risks. The change in ticker symbol and the new ownership structure (Clywedog stockholders owning 66%) signify a major transformation. Investors should maintain their current positions to observe the successful completion of the merger, the integration process, and the initial progress of the clinical milestones before making further investment decisions. The current stage warrants a cautious approach to observe execution and risk mitigation.

Keywords

Biotherapeutics, Immunology, Inflammation, Metabolic Diseases, Autoimmune Diseases, Diabetes, Celiac Disease, Merger, Acquisition, Clinical Stage, Drug Development, NASDAQ, CLYD, BRNS, OrbiMed, Torrey Pines